| Name | Title | Contact Details |
|---|
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We are headquartered in the UK and we also have operations in Germany and the US. Freeline was founded in 2015 and builds upon the pioneering work by our Clinical and Scientific Advisor and Director, Professor Amit Nathwani, Professor of Haematology at UCL. With our liver-based investigational gene therapy technology, we aim to improve the lives of people with chronic systemic diseases and realise the potential of gene therapy treatments.
Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. T
BIND Biosciences, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
arizonia infectious disease society is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.